Stephen Opat

11.0k total citations · 2 hit papers
158 papers, 2.7k citations indexed

About

Stephen Opat is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Stephen Opat has authored 158 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 95 papers in Pathology and Forensic Medicine, 87 papers in Genetics and 45 papers in Oncology. Recurrent topics in Stephen Opat's work include Lymphoma Diagnosis and Treatment (93 papers), Chronic Lymphocytic Leukemia Research (78 papers) and Immunodeficiency and Autoimmune Disorders (18 papers). Stephen Opat is often cited by papers focused on Lymphoma Diagnosis and Treatment (93 papers), Chronic Lymphocytic Leukemia Research (78 papers) and Immunodeficiency and Autoimmune Disorders (18 papers). Stephen Opat collaborates with scholars based in Australia, United States and New Zealand. Stephen Opat's co-authors include Constantine S. Tam, John F. Seymour, Judith Trotman, Michael Wenger, Carolyn Owen, Michael Herold, Wolfgang Hiddemann, Tom Moore, Günter Fingerle‐Rowson and Elizabeth H. Phillips and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Stephen Opat

138 papers receiving 2.7k citations

Hit Papers

Obinutuzumab for the Firs... 2017 2026 2020 2023 2017 2022 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
    2017 461 citations Stephen Opat, John F. Seymour et al. profile →
  2. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort
    2022 124 citations Constantine S. Tam, John N. Allan et al. Blood profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Stephen Opat 1.7k 1.4k 980 570 562 158 2.7k
Nishitha Reddy 1.4k 0.8× 1.0k 0.8× 1.0k 1.0× 511 0.9× 534 1.0× 116 2.3k
David Westerman 1.4k 0.8× 1.4k 1.0× 776 0.8× 732 1.3× 545 1.0× 125 2.8k
Wojciech Jurczak 2.3k 1.3× 1.6k 1.1× 1.5k 1.6× 529 0.9× 717 1.3× 281 3.4k
Carolyn Owen 1.8k 1.0× 2.1k 1.5× 702 0.7× 989 1.7× 782 1.4× 99 3.1k
Christian H. Geisler 1.8k 1.0× 1.2k 0.9× 1.1k 1.1× 305 0.5× 512 0.9× 52 2.4k
Rémy Gressin 1.7k 1.0× 880 0.6× 1.2k 1.2× 276 0.5× 561 1.0× 109 2.5k
Carlo Visco 1.5k 0.9× 1.1k 0.8× 1.1k 1.1× 329 0.6× 442 0.8× 108 2.4k
R. Gregory Bociek 1.7k 1.0× 927 0.7× 1.3k 1.3× 248 0.4× 420 0.7× 119 2.9k
Christiane Pott 2.5k 1.4× 1.5k 1.1× 1.8k 1.8× 816 1.4× 496 0.9× 132 3.7k
Timothy S. Fenske 1.2k 0.7× 624 0.5× 1.7k 1.7× 543 1.0× 522 0.9× 162 2.6k

Countries citing papers authored by Stephen Opat

Since Specialization
Citations

This map shows the geographic impact of Stephen Opat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen Opat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen Opat more than expected).

Fields of papers citing papers by Stephen Opat

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen Opat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen Opat. The network helps show where Stephen Opat may publish in the future.

Co-authorship network of co-authors of Stephen Opat

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen Opat. A scholar is included among the top collaborators of Stephen Opat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen Opat. Stephen Opat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Flinsenberg, T.W.H., Marie José Kersten, Jahanzaib Khwaja, et al.. (2025). Zanubrutinib in Bing Neel syndrome: efficacy and tolerability. Leukemia. 39(5). 1260–1264. 4 indexed citations
2.
Opat, Stephen, John Hrom, David Kliman, et al.. (2024). BGB-11417-203: An ongoing, phase 2 study of sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, in patients with Waldenström macroglobulinemia.. Journal of Clinical Oncology. 42(16_suppl). TPS7090–TPS7090. 3 indexed citations
3.
Opat, Stephen, John Hrom, David Kliman, et al.. (2024). BGB-11417-203, an Ongoing, Phase 2 Study of Sonrotoclax (BGB-11417), a Next-Generation BCL2 Inhibitor, in Patients With Waldenström Macroglobulinemia. Blood. 144(Supplement 1). 1661.1–1661.1. 1 indexed citations
4.
Lal, Luxi, Sriganesh Srihari, C. Raina MacIntyre, et al.. (2024). Comprehensive humoral and cellular immune responses to COVID-19 vaccination in adults with cancer. Vaccine. 46. 126547–126547. 4 indexed citations
5.
Roschewski, Mark, David M. Kurtz, Jason R. Westin, et al.. (2023). MRD‐NEGATIVITY AFTER FRONTLINE DLBCL THERAPY: POOLED ANALYSIS OF 6 CLINICAL TRIALS. Hematological Oncology. 41(S2). 177–179. 5 indexed citations
6.
Opat, Stephen, et al.. (2023). Hematologic Malignancy: Who Cares in the End? A Retrospective Cohort Study of Markers of Quality End-of-Life Care. Journal of the National Comprehensive Cancer Network. 21(8). 813–820.e1. 4 indexed citations
7.
Paul, Eldho, et al.. (2023). High risk of infection in ‘real‐world’ patients receiving ibrutinib, idelalisib or venetoclax for mature B‐cell leukaemia/lymphoma. European Journal Of Haematology. 110(5). 540–547. 4 indexed citations
8.
Shortt, Jake, et al.. (2023). P1678: INTERVENTIONS AND THERAPY AT END OF LIFE IN HAEMATOLOGICAL MALIGNANCY: A RETROSPECTIVE COHORT STUDY ON HEALTHCARE UTILISATION. HemaSphere. 7(S3). e86598b8–e86598b8. 1 indexed citations
9.
Tam, Constantine S., John N. Allan, Tanya Siddiqi, et al.. (2022). Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. Blood. 139(22). 3278–3289. 124 indexed citations breakdown →
10.
Odutola, Michael K., Marina T. van Leeuwen, Jennifer Turner, et al.. (2022). Associations between early-life growth pattern and body size and follicular lymphoma risk and survival: a family-based case-control study. Cancer Epidemiology. 80. 102241–102241. 2 indexed citations
11.
Sehn, Laurie H., Mark Hertzberg, Stephen Opat, et al.. (2021). Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data. Blood Advances. 6(2). 533–543. 107 indexed citations
12.
Gregory, Gareth P., Constantine S. Tam, Hang Quach, et al.. (2020). Excellent outcomes in older patients with primary CNS lymphoma treated with R-MPV/cytarabine without whole brain radiotherapy or autologous stem cell transplantation therapy. Leukemia & lymphoma. 62(1). 112–117. 8 indexed citations
13.
Trotman, Judith, Stephen Opat, David Gottlieb, et al.. (2020). Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up. Blood. 136(18). 2027–2037. 73 indexed citations
14.
15.
Cheah, Chan Y., Stephen Opat, Judith Trotman, & Paula Marlton. (2019). Front‐line management of indolent non‐Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphoma. Internal Medicine Journal. 49(9). 1070–1080. 10 indexed citations
16.
17.
Trotman, Judith, Chan Y. Cheah, Paula Marlton, & Stephen Opat. (2018). Front‐line management of non‐Hodgkin lymphoma in Australia. Part 1: follicular lymphoma. Internal Medicine Journal. 49(4). 422–433. 2 indexed citations
18.
Cull, Gavin, Stephen Opat, Judith Trotman, et al.. (2017). Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Combination with the PD-1 Inhibitor BGB-A317 in Patients with B-Cell Lymphoid Malignancies. Blood. 130. 4057–4057. 2 indexed citations
19.
Dendle, Claire, Michael Gilbertson, Tony M. Korman, et al.. (2015). Disseminated Enteroviral Infection Associated with Obinutuzumab. Emerging infectious diseases. 21(9). 1661–1663. 16 indexed citations
20.
Dawson, Mark A., Stephen Opat, Yamna Taouk, et al.. (2009). Clinical and Immunohistochemical Features Associated with a Response to Bortezomib in Patients with Multiple Myeloma. Clinical Cancer Research. 15(2). 714–722. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nishitha Reddy Breakdown of academic impact, for papers by David Westerman Breakdown of academic impact, for papers by Wojciech Jurczak Breakdown of academic impact, for papers by Carolyn Owen Breakdown of academic impact, for papers by Christian H. Geisler Breakdown of academic impact, for papers by Rémy Gressin Breakdown of academic impact, for papers by Carlo Visco Breakdown of academic impact, for papers by R. Gregory Bociek Breakdown of academic impact, for papers by Christiane Pott Breakdown of academic impact, for papers by Timothy S. Fenske
Rankless by CCL
2026